Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03850691 · ClinicalTrials.gov registry record · Phase 2
Radiation and Combination Immunotherapy for Melanoma
A Phase 2 study of Metastatic Melanoma, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
- 1
- Study location
NCT03850691 is a Phase 2 study of Metastatic Melanoma that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 4 participants, below the 84-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03850691, a Phase 2 study of Metastatic Melanoma, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 2 study designed to evaluate the combination of checkpoint blockade and aldesleukin (IL-2) therapy after a course of standard of care palliative radiation in the management of unresectable metastatic melanoma. To be eligible, a patient must have a minimum of 3 (preferably \>5) radiographically distinct, measurable (\>1.5 cm) lesions based on RECIST 1.1. Metastatic cutaneous melanoma must be refractory to standard immunotherapy drugs, molecular targeted agents and/or chemotherapy. Patients with ocular melanoma subtypes may enroll in this study without prior therapy, as there is no standard front-line therapy for this subset of patients.
Conditions Studied
Interventions
- DRUG Aldesleukin: All Patients
- DRUG Nivolumab: Cohort 1 (Cutaneous)
- DRUG Nivolumab: Cohort 2 (Ocular)
- DRUG Ipilimumab: Cohort 2 (Ocular)
Study Locations (1)
Minnesota
- University of Minnesota Masonic Cancer Center - Burnsville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2019-05-28 |
| Est. Completion | 2022-12-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03850691
The ClinicalTrials.gov registry entry for NCT03850691 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 84-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (95% lower). The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Melanoma appearing as the primary indexed condition, and to 4 interventions - of which Aldesleukin: All Patients is the first listed.
NCT03850691 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT03850691 about?
NCT03850691 is a clinical study titled "Radiation and Combination Immunotherapy for Melanoma". This is a Phase 2 study designed to evaluate the combination of checkpoint blockade and aldesleukin (IL-2) therapy after a course of standard of care palliative radiation in the management of unresectable metastatic melanoma. To be eligible, a patient must have a minimum of 3 (preferably \>5) radiog...
What is the current status of trial NCT03850691?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2019-05-28. Estimated completion is 2022-12-12.
What conditions does trial NCT03850691 study?
This clinical trial studies the following conditions: Metastatic Melanoma.
What interventions are being tested in trial NCT03850691?
The interventions under investigation include: Aldesleukin: All Patients (DRUG), Nivolumab: Cohort 1 (Cutaneous) (DRUG), Nivolumab: Cohort 2 (Ocular) (DRUG), Ipilimumab: Cohort 2 (Ocular) (DRUG).
Who is sponsoring clinical trial NCT03850691?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03850691 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
RECRUITING · Phase 2
-
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
RECRUITING · Phase 2
-
Cryoablation+Ipilimumab+Nivolumab in Melanoma
RECRUITING · Phase 2
-
Mirdametinib in Patients With Advanced NF1-mutant Melanoma
RECRUITING · Phase 2
-
Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma
RECRUITING · Phase 2
-
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.